CTCBIO Inc. (KOSDAQ:060590)

Market Cap	120.26B
Revenue (ttm)	132.76B
Net Income (ttm)	2.64B
Shares Out	23.91M
EPS (ttm)	110.61
PE Ratio	45.34
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,809
Average Volume	67,118
Open	5,040.00
Previous Close	5,030.00
Day's Range	4,990.00 - 5,060.00
52-Week Range	4,765.00 - 7,910.00
Beta	-0.08
RSI	44.01
Earnings Date	Nov 12, 2025

About CTCBIO

CTCBIO Inc. provides various pharmaceutical products in South Korea and internationally. The company offers animal and human pharmaceuticals; feed additives and ingredients; and functional food products. It also provides cardiovascular, gastrointestinal, osteoporosis, antibiotic, smoking cessation, antifungal and antiviral, antiepileptic, allergic rhinitis, dermatology and genito-urinory, allergic rhinitis and antihistamine, neuropsychiarty, intestinal disorders, X-ray, diabetes, anti-inflammatory and arthritis, and harmones, as well as CTC cov...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1993
• Employees: 248
• Stock Exchange: KOSDAQ
• Ticker Symbol: 060590

Financial Performance

In 2024, CTCBIO's revenue was 144.41 billion, an increase of 4.74% compared to the previous year's 137.88 billion. Losses were -5.22 billion, -66.51% less than in 2023.